Cidara Therapeutics — Leerink Partners Rare Disease & Immuno-Oncology Conference 2016
27 slides from Cidara Therapeutics's conference presentation, Sep 28, 2016

Slide 1: New Hope For Serious Infections
New Hope For Serious Infections Leerink Partners Rare Disease & Immuno-Oncology Conference Lotte New York Palace New York, NY September 28, 2016 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Exhibit 99.1

Slide 2: Forward-Looking Statements
Forward-Looking Statements These slides and the accompanying oral presentation (the “Presentation”) contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ

Slide 3: Two platforms, multiple programs
Two platforms, multiple programs 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 CD101 prophylaxis & other CD101 topical for VVC, Phase 2 CD101 IV for candidemia, Phase 2 CD101 IV for candidemia, Phase 2 CD101 topical for VVC, Phase 2 CD101 prophylaxis & other CD101 Echinocandin Ant

Slide 4: Fungal infections: high mortality
U.S. 12-Week Mortality per Annum by Species Fungal infections: high mortality 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Rare Fungi Cryptococcus Aspergillus Candida 2,500 4,500 22,500 67,500 97,000 deaths per year

Slide 5: Echinocandins: first line therapy for candidemia
Echinocandins: first line therapy for candidemia DRUG PROFILE First line treatment for Candida Safe and well tolerated Superior to azoles BUT CONSTRAINED Once daily IV Low exposure – suboptimal dosing Growing resistance USD Billions 4.2 0.5 1.1 2.6 Polyenes Echinocandins Azoles

Slide 6: CD101 opportunity: expand echinocandin market
CD101 opportunity: expand echinocandin market ACCESS ENTIRE >$4 BILLION MARKET Inpatient & outpatient Treatment & prophylaxis Penetrate azole class Expand indications 4.2 0.5 1.1 2.6 Polyenes Echinocandins Azoles ~2x USD Billions

Slide 7: CD101 – a differentiated echinocandin
CD101 – a differentiated echinocandin 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 ICAAC 2015 Prolongs PK Allows high exposures Eliminates toxic degradation products Enables multiple formulations once weekly dosing treats less susceptible pathogens improved safety & dose range sy

Slide 8: CD101 IV: streamlined development plan
CD101 IV: streamlined development plan 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 PK and safety in healthy volunteers Double-blind vs. echinocandin in candidemia Phase I Phase 2 Non-inferiority vs. echinocandin in candidemia IND I II III Phase 3 + invasive candidiasis

Slide 9: CD101 IV Phase I PK
AUC ~2.5x greater AUC ~1.6x higher Once weekly high exposure dosing CD101 IV Phase I PK Cmax 3x higher Anidulafungin 100mg x 7 400mg x 1 200mg x 1

Slide 10: Summary - CD101 IV Phase 1
No serious AEs No withdrawals due to AEs Summary - CD101 IV Phase 1 SAD/MAD Studies PK was dose-proportional and supports once weekly dosing No clinically significant laboratory abnormalities in any CD101 subject Adverse Events (AEs) similar between CD101 and placebo CD101 IV is safe and well-tolera

Slide 11: Phase 2: first of two studies for approval
Phase 2: first of two studies for approval CD101 IV 400/400/(400)mg 1 8 Dosing day 15 (optional) 5 Mycological response 14 Mycological & Clinical response 1o END POINT 28 Mycological & Clinical response 35 n=30 CD101 IV 400/200/(200)mg 1 8 Dosing day 15 (optional) 5 14 28 35 n=30 1 7 14 21 28 1 7 14

Slide 12: VVC/RVVC has widespread impact
VVC/RVVC has widespread impact 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 OTC Topical 75% have VVC in their lifetime US: 4-5M suffer RVVC Rx Topical or Oral US: 4.4M visits per year

Slide 13: Existing therapies have significant limitations
Existing therapies have significant limitations 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 30-40% women fail acute treatment 50% relapse in RVVC No coverage of non-albicans Candida Increased risk of miscarriage (flucon) CONFIDENTIAL CDC guidelines recommend only using topical a

Slide 14: Phase 2 VVC Study Design
Phase 2 VVC Study Design DAYS CD101 3% Gel CD101 6% Ointment Fluconazole 150mg 1 2 Dosing day 1 1 1 7 14 21 28 1 7 14 21 28 1 7 14 21 28 Efficacy 7 14 28 n=50 n=50 n=25 Objectives Safety/tolerability of CD101 Gel/Ointment Efficacy of CD101 Gel vs. CD101 Ointment vs. Fluconazole on Days 7, 14, 28 Myc

Slide 15: CD101 Topical development plan
CD101 Topical development plan Dose-ranging safety & efficacy in VVC patients Phase 2 Phase 3 Superiority in acute VVC 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 IND I II III Phase 3 Superiority in RVVC

Slide 16: Cloudbreak: antimicrobial immunotherapy
Cloudbreak: antimicrobial immunotherapy Physically connects the immune system with the pathogen Vaccine Primes the immune system Therapeutic Targets the pathogen The strengths of both systems Cloudbreak™ 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170

Slide 17: Cloudbreak: inspired by cancer immunotherapy
Cloudbreak: inspired by cancer immunotherapy Binds conserved cell surface target EFFECTOR MOIETY Engages innate or adaptive immune system TARGETING MOIETY Small & Large Molecule Microbe Cell 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 TM EM

Slide 18: Return to pre-antibiotic era for Gram negative infections
Return to pre-antibiotic era for Gram negative infections Nov Q1 2015 2016 Sources: Liu YY et al. Lancet Infect Dis. 2016 Feb;16(2):161-8. Du H Lancet Infect Dis. 2016 Jan 29. Yao X et al. Lancet Infect Dis. 2016 Jan 29, Bloomberg. AAC 2016 May 26 online; doi:10.1128/AAC.01103-16 Mcr-1 resistance pl

Slide 19: Cloudbreak antibacterial dual mechanism
Cloudbreak™ antibacterial dual mechanism Direct kill: novel TM tightly binds Gram-negative pathogens to kill bacteria 1

Slide 20: Cloudbreak antibacterial dual mechanism
Cloudbreak™ antibacterial dual mechanism Direct kill: novel TM tightly binds Gram-negative pathogens to kill bacteria Immunomodulatory: EM recruits and initiates an immune system response 1 2

Slide 21: CD201 has intrinsic antibacterial activity
CD201 has intrinsic antibacterial activity MIC90 against COL-susceptible KAPE pathogens (n=20/species) = 2-4 µg/mL MICs against MDR (aminoglycoside, CRE, COL incl. mcr-1) strains = 2-8 µg/mL CD201 has lower spontaneous mutation freq than COL at 2X MIC (<1.5E-09 vs 2.4E-09) Mutants do not show herita

Slide 22: CD201 efficacy: mouse E. coli septicemia model
CD201 efficacy: mouse E. coli septicemia model 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Mean log10 CFUs/g kidneys P<0.01 LOD 0 1 2 3 4 5 6 7 8 Vehicle + rAb Colistin 1 mpk CD201 3 mpk CD201 3 mpk + rAb

Slide 23: CD201 safety: rat toxicology study
CD201 safety: 5 day rat toxicology study 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 CD201 showed no significant histological changes in kidney or liver colistin showed mild to moderate proximal tubule degeneration Unlike colistin, CD201 does not substantially raise urinary albu

Slide 24: Cidara's development pipeline
Cidara’s development pipeline CD101 Cloudbreak™ IV Topical Antibacterial Antifungal Antiviral Discovery in vitro in vivo IND Enabling Phase 1 Phase 2

Slide 25: Financial Information
Financial Information 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Summary Information At 6/30/2016 Cash, cash equivalents and marketable securities $87.1 million Shares issued 14.0 million Fully-diluted shares1 16.1 million 1 Includes 2.1 million outstanding stock options; exclu

Slide 26: 2016 Milestones
2016 Milestones 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170 Program Next Milestone Expected Timing CD101 Topical Phase 2 start Mid 2016 ✓ CD101 IV Phase 2 Start Mid 2016 ✓ Cloudbreak Platform Development candidate Q4 2016 ✓

Slide 27: New Hope For Serious Infections
New Hope For Serious Infections Leerink Partners Rare Disease & Immuno-Oncology Conference Lotte New York Palace New York, NY September 28, 2016 186, 89, 21 43, 124, 154 28, 83, 102 102, 102, 102 170, 170, 170
Source: SEC EDGAR · 8-K filed Sep 28, 2016
More decks from Cidara Therapeutics Inc
Corporate Update (June 2025)12 slides · Jun 23, 2025
Investor Presentation (May 2024)63 slides · May 3, 2024
Investor Day (September 2023)58 slides · Sep 21, 2023
Investor Day (July 2022)57 slides · Jul 7, 2022
Technical Presentation (December 2021)24 slides · Dec 14, 2021
Investor Day (September 2021)110 slides · Sep 21, 2021